Skip to Content
You are currently on the new version of our website. Access the old version .
  • Review
  • Open Access

27 January 2026

21 Pages

New Insights into Neuromuscular Junction Biology: Evidence from Human and Animal Research

,
and
Institute of Pathology, RWTH Aachen University Hospital, 52074 Aachen, Germany
*
Author to whom correspondence should be addressed.

Abstract

Neuromuscular junctions (NMJs) are highly specialized synapses that enable efficient communication between motor neurons and skeletal muscle fibers. Impaired formation or maintenance of NMJs is implicated in the pathogenesis of multiple neuromuscular disorders and contributes to age-related declines in skeletal muscle mass and strength. NMJ functionality is governed by complex regulatory crosstalk among different cells and is mediated by a diverse network of proteins. Moreover, immune cells often reside at NMJs and exhibit phenotypically different characteristics depending on the regenerative state of the muscle. These complex interfaces have posed a significant challenge for elucidating pathogenic mechanisms and developing biomarkers or effective targeted treatments. Many animal models have been developed to address this challenge by characterizing the fundamental structural features of neuromuscular junctions (NMJs) and their transmission capacity under both healthy and disease conditions. In contrast, studies of human NMJs remain limited, although emerging evidence is increasingly revealing substantial morphological and functional differences from animal NMJs. This review provides an overview of animal research on NMJs over the past decades, highlighting interspecies differences and key advances in our understanding of human NMJs.

1. Introduction

Neuromuscular junctions (NMJs) are specialized cholinergic junctions in mammals that mediate skeletal muscle contraction through peripheral synapses. Situated at the terminus of motor axons, they enable rapid and reliable transmission of neural signals to drive both voluntary movements and involuntary reflexes. Therefore, the structural integrity and functional stability of NMJs are crucial for maintaining motor control and overall neuromuscular function.
Building on early descriptions of the “motor endplate” in frog muscles by Wilhelm Friedrich Kühne in 1862 [1], and foundational principles of synaptic physiology originating from invertebrate models by Bernard Katz’s pioneering work [2], NMJs have been examined in rodents, particularly in mice, since the 1970s [3]. Degenerative or dysfunctional changes in this microstructure are closely associated with multiple neuromuscular disorders and with age-related motor decline. Accumulating evidence from animal models indicates that the morphology and transmission efficiency of NMJs are not predetermined; instead, NMJs undergo continuous remodeling under diverse physiological and pathological contexts, including development, aging, autoimmunity, trauma, metabolic imbalance, and neurodegenerative conditions [4,5]. This plasticity highlights NMJs as dynamic and sensitive signaling hubs whose status may reflect the overall integrity of the neuromuscular system.
Recent animal studies have increasingly focused on the mechanisms that govern NMJ remodeling and regeneration, especially how nerve, muscle, and immune components interact to maintain synaptic stability or promote postdamage repair [6,7,8]. Understanding these intercellular and mechanical transduction processes in human NMJs [9,10] may provide a conceptual framework for the development of interventions aimed at maintaining or restoring neuromuscular connections in states of health, aging, and neuromuscular disorders such as myasthenia gravis (MG) [11], spinal muscular atrophy (SMA) [12], and amyotrophic lateral sclerosis (ALS) [13].

2. NMJ Structure and Regulatory Components

NMJs consist of three main domains: the presynaptic terminal of the motor neuron, the synaptic cleft, and the postsynaptic membrane of the muscle fiber (Figure 1) [14]. Additionally, NMJs are surrounded by different types of cells that possess diverse regulatory functions, including maintenance of the synaptic structure, early damage sensing, and regulation of inflammation. The best featured NMJ-associated cells are Schwann cells, named after the German physiologist Theodor Schwann. They play a crucial role in the development and maintenance of NMJs [6]. Other cells, including kranocytes and immune cells, are commonly found near NMJs [7,15]. However, their specific contributions to NMJ development and repair have yet to be systematically investigated. Other components, such as mast cells [16] and specialized myonuclei [17], also contribute to this complex regulatory environment.
Figure 1. Schematic representation of NMJ organization. Motor neurons extend toward the surface of muscle fibers and form clusters of terminal branches (upper left). Each NMJ consists of the presynaptic terminal of the motor neuron, the synaptic cleft, and the postsynaptic membrane of the muscle fiber associated with a myonucleus. Schwann cells, kranocytes, and macrophages are commonly found in close proximity to NMJs.

2.1. Presynaptic Terminals

Presynaptic motor endings mediate the synthesis, storage, and secretion of the neurotransmitter acetylcholine (ACh) (Figure 2). Early studies of NMJs in frog, zebra finch, and Chinese hamster have established that motor axons arise from neurons in the spinal cord and project toward skeletal muscle fibers, where they branch into terminal axonal endings that form specialized synaptic structures known as motor endplates [1]. Each synaptic body appears as a small spherical enlargement at the motor nerve terminal and is densely filled with synaptic vesicles that store ACh. In nerve endings, ACh is synthesized by choline acetyltransferase (ChAT), which drives the production of ACh from choline and acetyl coenzyme A.
Figure 2. Schematic presentation of neurotransmitter effects and signaling mechanisms within NMJ pre- and postsynaptic membranes.
Across vertebrate species, terminal axonal endings exhibit characteristic patterns of arborization. As motor axons approach the muscle surface, they disperse into multiple terminal branches that culminate in bouton-like swellings enriched in synaptic vesicles. This branching pattern establishes the core presynaptic architecture of the NMJ and determines the spatial distribution of neurotransmitter release sites along the postsynaptic membrane. Notably, compared with human NMJs, rodent NMJs are more complex and have more extensively branched terminal arbors. Human presynaptic terminals exhibit markedly simplified morphology with fewer branch points—reflecting a species-specific reduction in arbor complexity rather than diminished synaptic capacity [18,19].
In addition to spatial patterns, studies of mouse embryos revealed that presynaptic terminal composition is governed by molecular interactions, involving the binding of low-density lipoprotein receptor-related protein 4 (LRP4) to the CT domain of connective tissue growth factor (CTGF/CCN2) [20]. Loss-of-function analyses revealed that the connective tissue growth factor CTGF (CCN2) supports LRP4–MuSK signaling to maintain proper synaptic vesicle clustering within terminal boutons. In CTGF knockout (KO) mice, synaptic vesicles are distributed aberrantly along motor axons instead of being restricted to presynaptic endings [20]. These findings indicate that terminal arborization and bouton maturation depend on coordinated extracellular regulatory cues during development [20].
Murine presynaptic terminals have been extensively studied, leading to the identification of a variety of key proteins that regulate vesicle circulation and neurotransmitter release, including the core elements of the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex, the synaptic binding protein, and the synaptic vesicle protein 2 (SV2) [21]. These molecular mechanisms work together to mediate the biosynthesis, membrane fusion, and recycling of vesicle contents. Previous investigations in transgenic mouse models revealed that action potentials at nerve endings, followed by Ca2+ influx, initiate the fusion of neurotransmitter-filled synaptic vesicles, thereby facilitating rapid signal transmission across the synaptic cleft [21]. Furthermore, recent studies in mouse and cell culture models have indicated that additional proteins, including RIM, Munc13, and ELKS, form a dynamic molecular scaffold that couples Ca2+ influx with synaptic vesicle fusion, thereby regulating neurotransmitter release with nanometer-scale precision [22,23,24].
Recent high-speed imaging of single-channel Ca2+ nanodomains of the large reticulospinal presynaptic terminals in lamprey revealed that Ca2+ entry at individual active zones may be mediated by only a few—sometimes even a single—voltage-gated calcium channel [25]. Such single-channel nanodomains enable exceptionally tight spatial coupling between Ca2+ influx and synaptic vesicle fusion, thereby supporting the fast (1–4 ms) release kinetic characteristics of vertebrate NMJs [25].
Other studies in mouse and frog models have reported finely tuned mechanisms maintaining cholinergic homeostasis at the NMJ. In particular, acetylcholinesterase (AChE) is precisely distributed within the synaptic cleft, reflecting a tightly regulated microenvironment for ACh turnover [26]. These findings suggest that cholinergic synthesis activity may be dynamically regulated in response to exercise demands and neuronal activity.

2.2. Synaptic Cleft and Basal Lamina Structures

The synaptic gap is a narrow extracellular space that separates the presynaptic end from the postsynaptic muscle membrane. The synaptic cleft at the human NMJ was first described in ultrastructural detail by Murata and Ogata (1969), who demonstrated in the intercostal muscle that the narrow space between the presynaptic terminal and the tops of the junctional folds is filled with dense, basal-lamina-like material [14]. Comparative studies using both human primary myotubes and murine muscle cells have confirmed that laminin β2 and agrin cooperatively activate the MuSK–Lrp4 signaling axis to promote focal clustering of acetylcholine receptors (AChRs) at the postsynaptic membrane [27]. Consistently, human muscle biopsies from congenital myasthenic patients carrying AGRN or LRP4 mutations show disrupted AChR organization and fragmented basal lamina, which are phenotypes faithfully recapitulated in animal models, underscoring the conserved role of agrin–laminin–MuSK–Lrp4 signaling in NMJ development and long-term stability [28]. In cell culture experiments, agrin was capable of enhancing the internalization of MuSK and its downstream signals independently [29]. These findings suggest the involvement of a secondary regulatory pathway that can alter receptor turnover and postsynaptic membrane tissue [29].
The structural component of the basal membrane, collagen XIII, was implicated in NMJ repair in collagen XIII-deficient C57BL mice [30]. During NMJ formation, collagen XIII is crucial for not only the organization of the synaptic region but also the formation and regeneration of axons during the repair process [30]. Evidence from human muscle biopsies indicates that AChE—another key constituent of the synaptic basement membrane—is precisely localized along the synaptic cleft and postsynaptic folds, which is consistent with the conserved ultrastructural organization of the human NMJ [31]. This was assumed to ensure full hydrolysis of ACh by AChE, thus eliminating its reattachment to its receptor. Building upon earlier genomic studies that linked COLQ mutations to endplate AChE deficiency in humans [32,33], recent investigations using patient-derived muscle biopsies and iPSC models confirmed that C-terminal COLQ variants impair COLQ–LRP4 interactions, leading to defective AChE anchoring and abnormal synaptic organization at the human NMJ [34].

2.3. Postsynaptic Structural–Functional Domain

The postsynaptic membrane is a deeply in-folded specialized part of muscle fibers. Its main feature is extensive connections and folding, which significantly increase the area of receptor distribution and improve synaptic transmission efficiency. Studies in human tissue and cells have demonstrated that this site contains high concentrations of nicotinic AChRs (nAChRs) and various key regulatory proteins, including MuSK, LRP4, Dok-7, and Rapsyn [35]. These components work together to coordinate signal transduction related to aggregation, anchoring, and downstream receptors, helping to maintain the architecture and functional integrity of the NMJ.
ACh combines with nAChRs, leading to channel opening of non-selective cation, allowing Na+ influx and K+ efflux, generating an endplate potential. When the EPP reaches the threshold, Nav1.4 channels open, and the resulting action potential travels along the sarcolemma to initiate contraction, resulting in the translation of synaptic input into force [36,37]. Continuous structural research has improved this mechanism. Recent cryo-electron microscopy (cryo-EM) studies of human and mammalian nAChR have provided near-atomic insights into receptor architecture. Cryo-electron microscopy (cro-em) is capable of analyzing the substructures of nAChR with near-atomic precision and visualizing the conformational transitions during receptor activation and desensitization processes [38,39]. These structural findings clarify how chemical transmission is converted into electrical excitation at the NMJ and provide a basis for the structure-guided development of targeted modulators applicable to disorders such as myasthenia gravis.
Morphologically, motor nerve endings are embedded in the primary synaptic sulcus on the muscle surface, while the postsynaptic membrane protrudes inward to form secondary folds. These infoldings increase the size of the receptive surface and improve the efficiency of synaptic transmission. The acetylcholine receptor (AChR) is enriched on the crests of the junctional folds and positioned opposite presynaptic active zones, as confirmed in the human NMJ using expansion microscopy [40]. In contrast, Nav1.4 channels are concentrated deep within the folds in the mouse NMJ, facilitating local depolarization and reliable action-potential propagation [41]. Despite the existence of this clear spatial separation, the molecular mechanisms that determine the depth and periodicity of these folds remain unexplained. Recent evidence suggests that the AChR γ-to-ϵ subunit switch is critical for NMJ maturation, as incorporation of the ϵ-subunit promotes the stabilization and deepening of junctional folds, thereby establishing proper endplate morphology and periodicity [38,40].
Rodent research has shown that the formation of folds continues after birth, which may be related to the insertion of membranes rich in Nav1.4, which drive folds to expand inward [42]. In addition, super-resolution imaging has revealed that caveolin-3-dependent membrane infolding can occur even in the absence of nerve input, indicating a nerve-independent, lipid-raft driven mechanism for structural maturation [43]. Although these models are not mutually repulsive, they jointly emphasize the high regulation and dynamism of the postsynaptic membrane structure. During regeneration and repair, re-expression of the fetal γ-subunit transiently restores synaptic responsiveness and facilitates structural remodeling of the postsynaptic folds, suggesting that the subunit composition dynamically modulates NMJ recovery [37,44].

2.4. Terminal Schwann Cells: Key Regulators of NMJ Homeostasis and Repair

Schwann cells are non-myelinating glial cells that mainly wrap around the outer surface of the presynaptic terminal but also extend small protrusions around the synaptic gap, and some protrusions even reach the edge of the synaptic space [6,45]. Notably, presynaptic vesicles co-release ATP alongside acetylcholine; terminal Schwann cells (tSCs) sense this purinergic signal to trigger calcium-dependent signaling, thereby establishing the NMJ as a functional “tripartite synapse” where glial cells actively monitor and modulate synaptic activity [46,47]. These presynaptic Schwann cells (PSCs) play an indispensable regulatory role in the assembly, maturation, maintenance and regeneration of NMJs. Human histopathological studies corroborate these findings: in muscle biopsy samples from patients with amyotrophic lateral sclerosis, PSCs (presynaptic Schwann cells, also termed tSCs) exhibit abnormal cytoplasmic projections extending into the synaptic cleft, whereas in congenital myasthenic syndromes caused by LAMB2 or AGRIN mutations, tSCs are either absent or structurally disorganized [48,49].

2.5. Kranocytes: Structural Positioning and Functional Hypothesis

Court et al. [15] first systematically identified a group of extralayer cells above the NMJ, later known as synaptic kranocytes. Mouse and rat models were used for comparison with amphibian and avian NMJs. These cells are present in the junction area during the early development process and exhibit strong reactivity, proliferative ability, and migratory behavior after damage.
Experimental evidence suggests that synaptic nuclear cells may play a role in synaptic remodeling following nerve damage and are even activated before terminal Schwann cells initiate axon regeneration. These findings suggest that synaptic nuclear cells may play a role as early responders and regulators in the maintenance and repair of NMJs [15].

2.6. NMJ-Associated Myonuclei

In addition to the classic three-part structure of the NMJ—comprising the presynaptic terminal, synaptic space, and postsynaptic membrane—recent studies have identified a group of functionally specialized muscle nuclei located in the muscle fibers near the NMJ (approximately 10–40 µm in mice), called NMJ auxiliary nuclei [50].
In a recent single-cell and mononuclear transcriptomics study combining spatial positioning, researchers constructed a comprehensive spectrum of human skeletal muscle aging and identified several “specialized nuclear clusters”, including NMJ auxiliary nuclei. The expansion of the distribution of these nuclei in the muscles of elderly individuals may reflect the compensatory redomination response to age-related denervation [17]. In contrast, during disuse atrophy, such as bed rest, myonuclear domains shrink, while subsynaptic myonuclei are preferentially preserved, maintaining NMJ integrity and enabling faster recovery upon reactivation [51,52].

2.7. NMJ-Associated Immune Cells

Previous studies reported the increased accumulation of mast cells and macrophages near degenerating motor axons and NMJs in a amyotrophic lateral sclerosis (ALS) rat model [37]. Furthermore, the accumulation of mast cells and macrophages was successfully prevented by systemic treatment with masitinib, a tyrosine kinase inhibitor that has shown beneficial effects in clinical trials for ALS [37]. In rodents, peripheral nerve injury induces immune activation within muscle, including macrophage accumulation near denervated endplates [7]. These findings provided evidence for the implication of mast cells and macrophages in distal axonopathy. Consistent with these findings, nerve injuries led to macrophage accumulation close to NMJs in an ALS mouse model [16,53]. In another ALS mouse model, sustained immune activation around degenerating NMJs was associated with impaired regeneration, while immune modulation partially preserves NMJ structure [54]. Mechanistically, macrophages facilitate the clearance of synaptic debris and modulate the inflammatory milieu that supports axonal regrowth and endplate remodeling [8]. Although these observations propose immune cell infiltration and NMJ instability as potential pathogenic defects in rodents, their role in the human system is unknown. Studies of human skeletal muscle established the implication of tissue-resident macrophage populations in aging, chronic inflammation, and tissue regeneration [55,56,57]. Although NMJ instability and immune dysregulation frequently co-occur in human aging and neuromuscular diseases, the functional relevance of perisynaptic macrophages in humans remains to be established.

2.8. Interspecies Differences

Recent studies using high-resolution imaging and proteomics have reported significant structural differences between NMJs in humans and those in other species. Among the NMJs of all studied mammalian species, human NMJs are the smallest and have the lowest quantity of ACh discharged by a nerve impulse, which is less than 50% that of mice [18]. Furthermore, although the terminal plate area of human NMJs is considerably smaller despite the greater diameter of human muscle fibers, this limitation is likely compensated by deeper and more intricate junctional infoldings [19]. These morphological specializations substantially expand the postsynaptic surface area—by approximately eightfold—thereby increasing receptor density and enhancing synaptic transmission efficiency.
Detailed morphological analysis revealed that the human NMJ shows a higher degree of fragmentation, longer presynaptic axons, and simpler neural endings, and its terminal plate has a discrete “coin-shaped” structure [18]. Extensive folding of the postsynaptic membrane significantly increases the density of the AChR, thus optimizing the synaptic performance in a compact structure [40].
Boehm et al. conducted a comparative analysis of six mammals, including humans, human-like primates, and standard experimental animals, and the results revealed significant interspecific heterogeneity in the volume and morphology of the NMJ [19]. In this study, the average area of the human NMJ terminal plate was approximately 194 μm2, and the postsynaptic membrane area was 99 μm2, both of which are significantly smaller than those of mice (387 μm2 and 237 μm2 respectively), although the diameter of human muscle fibers was larger (53 μm vs. 30 μm) [19].
Notably, the NMJ of mice is the largest and most complex “pretzel-like” terminal form, whereas the NMJ of cats is the smallest. In contrast, the NMJs of sheep and pigs are similar and more closely related to the structure of human NMJs, indicating that large animal models may provide a more representative and transformative system for the study of the physiology and pathology of human NMJ.
Furthermore, comparative analyses revealed substantial morphological heterogeneity of NMJs across species and among different muscle groups within the same species. This variability is believed to mainly stem from the intrinsic characteristics of the motor neurons themselves rather than the differences in muscle fiber types. Table 1 provides a comparative overview of studies on NMJ structural and regulatory components across different experimental models, linking mechanistic targets to disease contexts and potential clinical translation.
Table 1. Experimental and Clinical Evidence Linking NMJ Structure and Function Across Species and Disease Contexts.

3. NMJ Remodeling and Regeneration

3.1. NMJ Structural Remodeling and Adaptation

The neuromuscular junction (NMJ), once regarded as a rigid and structurally fixed synapse, is now understood to be a highly dynamic and plastic interface capable of extensive structural and functional remodeling. This intrinsic plasticity allows the NMJ to adjust its synaptic efficacy and architecture in response to developmental signals, changes in mechanical load, metabolic challenges, or pathological conditions. Through such remodeling, the NMJ preserves reliable motor output across a wide spectrum of physiological states.
In rodent models, NMJ properties undergo continuous adaptive modification in response to altered contractile demands [66]. Increased neuromuscular activity during sustained or high-intensity exercise promotes synaptic expansion and increases the density of active zones and the efficiency of neurotransmission [66]. Deepening of postsynaptic junctional folds represents a key structural adaptation closely linked to improved synaptic performance. Conversely, prolonged disuse or mechanical unloading induces presynaptic atrophy, reduced terminal arborization, and disruption of postsynaptic AChR organization, collectively diminishing synaptic efficacy and accelerating functional decline [65]. In humans, endurance training increases the stability and transmission efficiency of terminal-plate AChRs. Electrophysiological indices—including compound muscle action potential (CMAP) amplitude and tremor characteristics—also improve with training, demonstrating that the human NMJ exhibits measurable functional plasticity [60].
Furthermore, recent injury model studies have demonstrated that presynaptic and postsynaptic compartments display asymmetric structural susceptibility to toxic or metabolic stress [68]. In a toxin-induced NMJ injury model in adult mice, presynaptic nerve-terminal branching remained largely intact despite significant neuromuscular damage, whereas postsynaptic AChR domains exhibited marked reductions in endplate area, decreased perimeter length, and increased spatial fragmentation [68]. These observations indicate that, under pathological conditions, the presynaptic terminal often retains much of its architectural integrity, whereas the postsynaptic membrane undergoes predominant structural remodeling during both degenerative and reparative processes.
To date, multiple regulatory pathways have been implicated in the maintenance and regenerative capacity of NMJ:
  • Multiscale regulatory networks
Evidence from human neuromuscular tissue and ex vivo reinnervation models indicates that ECM remodeling and metabolic signaling jointly shape the regenerative potential of the NMJ, supporting a multilayered model of synaptic regulatory control [64].
  • Metabolic signaling
The AMPK–PGC-1α axis integrates metabolic cues to regulate synaptic gene expression and AChR clustering, with its activity tightly modulated by contractile load and metabolic stress [65,67].
  • Mechanotransduction
YAP/TAZ–TEAD signaling, together with focal adhesion kinase (FAK), maintains endplate architecture, stimulates synaptic-nuclear transcription, and reinforces cytoskeletal anchoring in response to mechanical loading [17].
  • Neurotrophic cascades
Neurotrophic factors converge on the PI3K–Akt and MAPK pathways to preserve axonal integrity, promote AChR clustering, and sustain synaptic activation, thereby supporting NMJ stabilization during injury or metabolic stress [71].
  • ECM-dependent control
Assembly and maintenance of the NMJ ECM are governed primarily by the agrin–LRP4–MuSK pathway, which establishes a molecular scaffold linking presynaptic release sites with postsynaptic AChR clusters. Human agrin–LRP4–MuSK complexes form stable supramolecular structures that remain responsive to fluctuations in the metabolic state [62].
  • Muscle membrane mechanosensation
Beyond canonical integrin–FAK and YAP/TAZ signaling, the muscle membrane exhibits intrinsic mechanosensory properties that can prime the postsynaptic apparatus. Dynamic exposure of phosphatidylserine (PS) at the muscle surface acts as a molecular switch activating the mechanosensitive channel PIEZO1, driving Ca2+ influx and promoting myotube morphogenesis and membrane maturation. This mechanism illustrates how biophysical membrane properties and mechanotransduction directly support the postsynaptic remodeling of AChR domains [73]. Subsequent studies using genetic mouse models established a central role for PIEZO1 in muscle regeneration and satellite-cell activation via Rho-dependent signaling [10].
Collectively, these regulatory mechanisms define an integrated structure–function–adaptive framework in skeletal muscle that operates independently of the classical nerve-regeneration program. Whereas acute NMJ repair re-establishes synaptic connectivity and neurotransmitter release, these long-acting regulatory networks maintain the stability, resilience, and functional adaptability of NMJs across aging, shifts in mechanical demand, and metabolic stress.

3.2. NMJ Repair and Reinnervation

Successful reinnervation of the NMJ can occur following peripheral nerve injury in animal models. Nevertheless, the loss of neural input rapidly induces muscle fiber atrophy, disintegration of postsynaptic specialization, and disruption of intramuscular axons, ultimately compromising the efficiency of excitation–contraction coupling [74]. In parallel, studies in humans have indicated that the expression of acetylcholine receptor (AChR) subunits decreases, the number of postsynaptic folds declines, and synaptic transmission weakens following denervation [52]. During the subsequent process of reinnervation, regenerating motor axons rely on the residual presynaptic architectural framework to navigate back to their original synaptic territory. At this stage, terminal Schwann cells (tSCs) play a pivotal role. They undergo injury-induced morphological remodeling, extend dynamic cytoplasmic processes, and form directional guidance structures that channel nascent axonal sprouts toward the motor endplate, thereby ensuring the precision of synaptic reestablishment [75,76]. Furthermore, recent investigations of human NMJs—including those collected from the peroneus brevis muscle during lower-limb amputations and complemented by rectus abdominis samples from abdominal surgeries—confirm that tSCs consistently cap the adult human NMJ and display species-specific morphological features relevant to synaptic stability and remodeling [63]. Once regenerating axon terminals re-establish contact with muscle fibers, the presynaptic membrane reconstructs its active zones to support synchronous acetylcholine release. Concurrently, AChRs recluster within the postsynaptic membrane, and junctional folds are gradually reformed, collectively restoring effective neuromuscular transmission.
Functional NMJ recovery requires not only the reconstitution of its anatomical architecture but also the coordinated maturation of its biomechanical and electrophysiological properties. During the early stages of reinnervation, the NMJ structure remains fragile, and its physiological function is incompletely developed. As motor activity increases, mechanotransduction pathways—including focal adhesion kinase (FAK), the transcriptional coactivators YAP/TAZ, and integrin-dependent signaling cascades—are progressively activated. These pathways reinforce cytoskeletal anchoring, refine synaptic organization, and ultimately increase the stability and reliability of neuromuscular transmission [9]. Notably, although these mechanotransductive pathways have been well characterized in animal models and in human skeletal muscle more broadly, their direct involvement in adult human NMJ has not yet been experimentally demonstrated.
Growing clinical and histological evidence indicates that the extent of motor functional recovery is closely linked to the structural and functional stability of the NMJ. Intraoperative analyses of human upper-limb muscle biopsies—including those of the biceps brachii, flexor carpi, and abductor pollicis muscles—have shown that the preservation of motor endplates strongly predicts superior postoperative outcomes following peripheral nerve transfer surgery [77]. Consistently, biopsy studies of the human vastus lateralis muscle have shown that molecular destabilization of the NMJ parallels reductions in muscle contractile performance during periods of disuse, whereas reactivation through resistance training restores NMJ stability and increases synaptic transmission capacity [44]. On the other hand, the coordinated regeneration of axons, terminal Schwann cells, and postsynaptic structures supports the orderly reconstruction of the synapse, enabling the NMJ to recover its transmission efficacy and fatigue resistance, thereby sustaining normal muscle contractile function [44].

5. Conclusions and Future Perspectives

Elucidating the mechanisms of neuromuscular junction communication in health and disease is essential for the development of effective therapies for neuromuscular disorders. However, current understanding of human NMJ remains incomplete, largely because animal models exhibit heterogeneous synaptic morphologies and substantial age- or disease-related variability. Evidence from correlation studies indicates that large animal models may be more appropriate and accurate for understanding human NMJs and can lead to new insights into NMJ biology. Future advances will require systematic analyses of NMJs across diverse human muscles, developmental stages, and health conditions to clarify the mechanisms governing regeneration and neuronal remodeling. The evidence reviewed herein indicates that NMJ transmission instability can precede overt muscle atrophy, highlighting the need for longitudinal studies that directly link synaptic dysfunction to impaired recovery during aging. The development of new approaches that overcome the limitations of previous human studies will accelerate our understanding of NMJ repair and related diseases. The validation of electrophysiological and circulating biomarkers—including tremor characteristics, iMUNE, CAF, and NfL—may facilitate early risk stratification and the assessment of regenerative potential. Therapeutic strategies aimed at stabilizing agrin–LRP4–MuSK signaling or increasing reinnervation represent promising human-centered approaches for preserving NMJ connectivity and supporting functional recovery across the lifespan.

Author Contributions

Conceptualization, Z.L. and M.N.; methodology, Z.L.; investigation, Z.L. and X.C.; writing—original draft preparation, Z.L.; writing—review and editing, Z.L., X.C. and M.N.; visualization, Z.L.; supervision, M.N. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by START Grants from RWTH Aachen University Hospital (No. 111/25), China Scholarship Council (No. 202206170014), and Guangzhou Panyu Fifth People’s Hospital Scholarship (No. 440181198912140017). The funding bodies played no role in the design or writing of the manuscript.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
AChAcetylcholine
AChEAcetylcholinesterase
AChRAcetylcholine Receptor
AktProtein Kinase B (AKT)
ALSAmyotrophic Lateral Sclerosis
AMPKAMP-Activated Protein Kinase
ATPAdenosine Triphosphate
AZActive Zone
CAFC-terminal Agrin Fragment
Cav3Caveolin-3
CCN2/CTGFCellular Communication Network Factor 2/Connective Tissue Growth Factor
ChATCholine Acetyltransferase
CMAPCompound Muscle Action Potential
COLQCollagen Q (AChE-anchoring collagen)
cryo-EMCryo-Electron Microscopy
Dok-7Downstream of Tyrosine Kinase 7
ECMExtracellular Matrix
EPPEndplate Potential
EMGElectromyography
FAKFocal Adhesion Kinase
iMUNEMotor Unit Number Estimation (incremental MUNE)
IL-6Interleukin-6
iPSCInduced Pluripotent Stem Cell
LRP4Low-Density Lipoprotein Receptor-Related Protein 4
MAPKMitogen-Activated Protein Kinase
MuSKMuscle-Specific Kinase
Munc13/Munc18Mammalian Unc-13/Unc-18 homologs
nAChRNicotinic Acetylcholine Receptor
Nav1.4Skeletal-Muscle Voltage-Gated Sodium Channel α-subunit
NCAMNeural Cell Adhesion Molecule
NfLNeurofilament Light Chain
NMJNeuromuscular Junction
PI3KPhosphoinositide 3-Kinase
PSCPerisynaptic Schwann Cell
PGC-1αPeroxisome Proliferator-Activated Receptor Gamma Coactivator-1α
RIMRab3-Interacting Molecule
ROSReactive Oxygen Species
SCSatellite Cell
SNARESoluble NSF Attachment Protein Receptor
SV2Synaptic Vesicle Glycoprotein 2
TAZTranscriptional Co-Activator with PDZ-binding motif
TNF-αTumor Necrosis Factor-α
tSCTerminal Schwann Cell
VGCCVoltage-Gated Calcium Channel
YAPYes-Associated Protein
MGMyasthenia gravis
SMASpinal muscular atrophy

References

  1. Desaki, J.; Uehara, Y. The overall morphology of neuromuscular junctions as revealed by scanning electron microscopy. J. Neurocytol. 1981, 10, 101–110. [Google Scholar] [CrossRef] [Scilit]
  2. Katz, B.; Kuffler, S.W. Excitation of the nerve-muscle system in Crustacea. Proc. R. Soc. Lond B Biol. Sci. 1946, 133, 374–389. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Fertuck, H.C.; Salpeter, M.M. Localization of acetylcholine receptor by 125I-labeled alpha-bungarotoxin binding at mouse motor endplates. Proc. Natl. Acad. Sci. USA 1974, 71, 1376–1378. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Tisdale, S.; Van Alstyne, M.; Simon, C.M.; Mentis, G.Z.; Pellizzoni, L. SMN controls neuromuscular junction integrity through U7 snRNP. Cell Rep. 2022, 40, 111393. [Google Scholar] [CrossRef] [Scilit]
  5. Reuveni, D.; Aricha, R.; Souroujon, M.C.; Fuchs, S. MuSK EAMG: Immunological Characterization and Suppression by Induction of Oral Tolerance. Front. Immunol. 2020, 11, 403. [Google Scholar] [CrossRef] [Scilit]
  6. Barik, A.; Li, L.; Sathyamurthy, A.; Xiong, W.C.; Mei, L. Schwann Cells in Neuromuscular Junction Formation and Maintenance. J. Neurosci. 2016, 36, 9770–9781. [Google Scholar] [CrossRef] [Scilit]
  7. Lu, C.Y.; Santosa, K.B.; Jablonka-Shariff, A.; Vannucci, B.; Fuchs, A.; Turnbull, I.; Pan, D.; Wood, M.D.; Snyder-Warwick, A.K. Macrophage-Derived Vascular Endothelial Growth Factor-A Is Integral to Neuromuscular Junction Reinnervation after Nerve Injury. J. Neurosci. 2020, 40, 9602–9616. [Google Scholar] [CrossRef] [Scilit]
  8. Cunningham, M.E.; Meehan, G.R.; Robinson, S.; Yao, D.; McGonigal, R.; Willison, H.J. Perisynaptic Schwann cells phagocytose nerve terminal debris in a mouse model of Guillain-Barre syndrome. J. Peripher. Nerv. Syst. 2020, 25, 143–151. [Google Scholar] [CrossRef] [Scilit]
  9. Gessler, L.; Huraskin, D.; Jian, Y.; Eiber, N.; Hu, Z.; Proszynski, T.J.; Hashemolhosseini, S. The YAP1/TAZ-TEAD transcriptional network regulates gene expression at neuromuscular junctions in skeletal muscle fibers. Nuclei. Acids Res. 2024, 52, 600–624. [Google Scholar] [CrossRef] [Scilit]
  10. Hirano, K.; Tsuchiya, M.; Shiomi, A.; Takabayashi, S.; Suzuki, M.; Ishikawa, Y.; Kawano, Y.; Takabayashi, Y.; Nishikawa, K.; Nagao, K.; et al. The mechanosensitive ion channel PIEZO1 promotes satellite cell function in muscle regeneration. Life Sci. Alliance 2023, 6, e202201783. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  11. Li, H.; Pham, M.C.; Teng, J.; O’Connor, K.C.; Noviello, C.M.; Hibbs, R.E. Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures. Cell 2025, 188, 2390–2406.e20. [Google Scholar] [CrossRef] [Scilit]
  12. Grimaldi, L.; Garcia-Uzquiano, R.; de la Banda, M.G.; Oulhissane-Omar, A.; Tard, C.; Saugier-Veber, P.; Laugel, V.; Desguerre, I.; Cintas, P.; Vuillerot, C.; et al. REGISTRE SMA FRANCE: A nationwide observational registry of patients with spinal muscular atrophy in France. J. Neuromuscul. Dis. 2025, 12, 793–803. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  13. Gendron, T.F.; Petrucelli, L. Immunological drivers of amyotrophic lateral sclerosis. Sci. Transl. Med. 2023, 15, eadj9332. [Google Scholar] [CrossRef] [Scilit]
  14. Murata, F.; Ogata, T. The ultrastructure of neuromuscular junctions of human red, white and intermediate striated muscle fibers. Tohoku J. Exp. Med. 1969, 99, 289–301. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Court, F.A.; Gillingwater, T.H.; Melrose, S.; Sherman, D.L.; Greenshields, K.N.; Morton, A.J.; Harris, J.B.; Willison, H.J.; Ribchester, R.R. Identity, developmental restriction and reactivity of extralaminar cells capping mammalian neuromuscular junctions. J. Cell Sci. 2008, 121, 3901–3911. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Trias, E.; Ibarburu, S.; Barreto-Nunez, R.; Varela, V.; Moura, I.C.; Dubreuil, P.; Hermine, O.; Beckman, J.S.; Barbeito, L. Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. JCI Insight 2017, 2, e95934. [Google Scholar] [CrossRef] [Scilit]
  17. Kedlian, V.R.; Wang, Y.; Liu, T.; Chen, X.; Bolt, L.; Tudor, C.; Shen, Z.; Fasouli, E.S.; Prigmore, E.; Kleshchevnikov, V.; et al. Human skeletal muscle aging atlas. Nat. Aging 2024, 4, 727–744. [Google Scholar] [CrossRef] [Scilit]
  18. Jones, R.A.; Harrison, C.; Eaton, S.L.; Llavero Hurtado, M.; Graham, L.C.; Alkhammash, L.; Oladiran, O.A.; Gale, A.; Lamont, D.J.; Simpson, H.; et al. Cellular and Molecular Anatomy of the Human Neuromuscular Junction. Cell Rep. 2017, 21, 2348–2356. [Google Scholar] [CrossRef] [Scilit]
  19. Boehm, I.; Alhindi, A.; Leite, A.S.; Logie, C.; Gibbs, A.; Murray, O.; Farrukh, R.; Pirie, R.; Proudfoot, C.; Clutton, R.; et al. Comparative anatomy of the mammalian neuromuscular junction. J. Anat. 2020, 237, 827–836. [Google Scholar] [CrossRef] [Scilit]
  20. Ohkawara, B.; Kobayakawa, A.; Kanbara, S.; Hattori, T.; Kubota, S.; Ito, M.; Masuda, A.; Takigawa, M.; Lyons, K.M.; Ishiguro, N.; et al. CTGF/CCN2 facilitates LRP4-mediated formation of the embryonic neuromuscular junction. EMBO. Rep. 2020, 21, e48462. [Google Scholar] [CrossRef] [Scilit]
  21. Lai, Y.; Choi, U.B.; Leitz, J.; Rhee, H.J.; Lee, C.; Altas, B.; Zhao, M.L.; Pfuetzner, R.A.; Wang, A.L.; Brose, N.; et al. Molecular Mechanisms of Synaptic Vesicle Priming by Munc13 and Munc18. Neuron 2017, 95, 591–607.e10. [Google Scholar] [CrossRef] [Scilit]
  22. Wu, S.S.; Fan, J.L.; Tang, F.J.; Chen, L.; Zhang, X.Y.; Xiao, D.Q.; Li, X.H. The role of RIM in neurotransmitter release: Promotion of synaptic vesicle docking, priming, and fusion. Front. Neurosci. 2023, 17, 1123561. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Sakamoto, H.; Ariyoshi, T.; Kimpara, N.; Sugao, K.; Taiko, I.; Takikawa, K.; Asanuma, D.; Namiki, S.; Hirose, K. Synaptic weight set by Munc13-1 supramolecular assemblies. Nat. Neurosci. 2018, 21, 41–49. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Kawabe, H.; Mitkovski, M.; Kaeser, P.S.; Hirrlinger, J.; Opazo, F.; Nestvogel, D.; Kalla, S.; Fejtova, A.; Verrier, S.E.; Bungers, S.R.; et al. ELKS1 localizes the synaptic vesicle priming protein bMunc 13-2 to a specific subset of active zones. J. Cell Biol. 2017, 216, 1143–1161, Correction in J. Cell Biol. 2017, 216, 1205. https://doi.org/10.1083/jcb.20160608603092017c. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Ramachandran, S.; Rodgriguez, S.; Potcoava, M.; Alford, S. Single Calcium Channel Nanodomains Drive Presynaptic Calcium Entry at Lamprey Reticulospinal Presynaptic Terminals. J. Neurosci. 2022, 42, 2385–2403. [Google Scholar] [CrossRef] [Scilit]
  26. Blotnick-Rubin, E.; Anglister, L. Fine Localization of Acetylcholinesterase in the Synaptic Cleft of the Vertebrate Neuromuscular Junction. Front. Mol. Neurosci. 2018, 11, 123. [Google Scholar] [CrossRef] [Scilit]
  27. Pezinski, M.; Daszczuk, P.; Pradhan, B.S.; Lochmuller, H.; Proszynski, T.J. An improved method for culturing myotubes on laminins for the robust clustering of postsynaptic machinery. Sci. Rep. 2020, 10, 4524. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Barik, A.; Lu, Y.; Sathyamurthy, A.; Bowman, A.; Shen, C.; Li, L.; Xiong, W.C.; Mei, L. LRP4 is critical for neuromuscular junction maintenance. J. Neurosci. 2014, 34, 13892–13905, Correction in J. Neurosci. 2015, 35, 7655. [Google Scholar] [CrossRef] [Scilit]
  29. Gemza, A.; Barresi, C.; Proemer, J.; Hatami, J.; Lazaridis, M.; Herbst, R. Internalization of Muscle-Specific Kinase Is Increased by Agrin and Independent of Kinase-Activity, Lrp4 and Dynamin. Front. Mol. Neurosci. 2022, 15, 780659. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Zainul, Z.; Heikkinen, A.; Koivisto, H.; Rautalahti, I.; Kallio, M.; Lin, S.; Härönen, H.; Norman, O.; Rüegg, M.A.; Tanila, H.; et al. Collagen XIII Is Required for Neuromuscular Synapse Regeneration and Functional Recovery after Peripheral Nerve Injury. J. Neurosci. 2018, 38, 4243–4258. [Google Scholar] [CrossRef] [Scilit]
  31. Logan, C.V.; Cossins, J.; Rodriguez Cruz, P.M.; Parry, D.A.; Maxwell, S.; Martinez-Martinez, P.; Riepsaame, J.; Abdelhamed, Z.A.; Lake, A.V.; Moran, M.; et al. Congenital Myasthenic Syndrome Type 19 Is Caused by Mutations in COL13A1, Encoding the Atypical Non-fibrillar Collagen Type XIII alpha1 Chain. Am. J. Hum. Genet. 2015, 97, 878–885. [Google Scholar] [CrossRef] [Scilit]
  32. Nakata, T.; Ito, M.; Azuma, Y.; Otsuka, K.; Noguchi, Y.; Komaki, H.; Okumura, A.; Shiraishi, K.; Masuda, A.; Natsume, J.; et al. Mutations in the C-Terminal Domain of ColQ in Endplate Acetylcholinesterase Deficiency Compromise ColQ-MuSK Interaction. Hum. Mutat. 2013, 34, 997–1004. [Google Scholar] [CrossRef] [Scilit]
  33. Wargon, I.; Richard, P.; Kuntzer, T.; Sternberg, D.; Nafissi, S.; Gaudon, K.; Lebail, A.; Bauche, S.; Hantaï, D.; Fournier, E.; et al. Long-term follow-up of patients with congenital myasthenic syndrome caused by mutations. Neuromuscul. Disord. 2012, 22, 318–324. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Barbeau, S.; Semprez, F.; Dobbertin, A.; Merriadec, L.; Roussange, F.; Eymard, B.; Sternberg, D.; Fournier, E.; Karasoy, H.; Martinat, C.; et al. Molecular Analysis of a Congenital Myasthenic Syndrome Due to a Pathogenic Variant Affecting the C-Terminus of ColQ. Int. J. Mol. Sci. 2023, 24, 16217. [Google Scholar] [CrossRef] [Scilit]
  35. Ohkawara, B.; Shen, X.; Selcen, D.; Nazim, M.; Bril, V.; Tarnopolsky, M.A.; Brady, L.; Fukami, S.; Amato, A.A.; Yis, U.; et al. Congenital myasthenic syndrome-associated agrin variants affect clustering of acetylcholine receptors in a domain-specific manner. JCI Insight 2020, 5, e132023. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  36. Pan, N.C.; Zhang, T.; Hu, S.; Liu, C.; Wang, Y. Fast desensitization of acetylcholine receptors induced by a spider toxin. Channels 2021, 15, 507–515. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Cisterna, B.A.; Vargas, A.A.; Puebla, C.; Fernandez, P.; Escamilla, R.; Lagos, C.F.; Matus, M.F.; Vilos, C.; Cea, L.A.; Barnafi, E.; et al. Active acetylcholine receptors prevent the atrophy of skeletal muscles and favor reinnervation. Nat. Commun. 2020, 11, 1073. [Google Scholar] [CrossRef] [Scilit]
  38. Li, A.; Pike, A.C.W.; Webster, R.; Maxwell, S.; Liu, W.W.; Chi, G.; Palace, J.; Beeson, D.; Sauer, D.B.; Dong, Y.Y. Structures of the human adult muscle-type nicotinic receptor in resting and desensitized states. Cell Rep. 2025, 44, 115581. [Google Scholar] [CrossRef] [Scilit]
  39. Noviello, C.M.; Gharpure, A.; Mukhtasimova, N.; Cabuco, R.; Baxter, L.; Borek, D.; Sine, S.M.; Hibbs, R.E. Structure and gating mechanism of the alpha7 nicotinic acetylcholine receptor. Cell 2021, 184, 2121–2134.e13. [Google Scholar] [CrossRef] [Scilit]
  40. Ramadan, A.; Sheard, T.M.D.; Alhindi, A.; Rust, P.A.; Jones, R.A.; Jayasinghe, I.; Gillingwater, T.H. Expansion microscopy reveals nano-scale insights into the human neuromuscular junction. Cell Rep. Methods 2025, 5, 101082. [Google Scholar] [CrossRef] [Scilit]
  41. York, A.L.; Zheng, J.Q. Super-Resolution Microscopy Reveals a Nanoscale Organization of Acetylcholine Receptors for Trans-Synaptic Alignment at Neuromuscular Synapses. eNeuro 2017, 4, 78–88. [Google Scholar] [CrossRef] [Scilit]
  42. Zhang, C.; Joshi, A.; Liu, Y.; Sert, O.; Haddix, S.G.; Teliska, L.H.; Rasband, A.; Rodney, G.G.; Rasband, M.N. Ankyrin-dependent Na(+) channel clustering prevents neuromuscular synapse fatigue. Curr. Biol. 2021, 31, 3810–3819.e3814. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  43. Kwan, H.R.; Chan, Z.C.; Bi, X.; Kutkowska, J.; Proszynski, T.J.; Chan, C.B.; Lee, C.W. Nerve-independent formation of membrane infoldings at topologically complex postsynaptic apparatus by caveolin-3. Sci. Adv. 2023, 9, eadg0183. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  44. Sarto, F.; Stashuk, D.W.; Franchi, M.V.; Monti, E.; Zampieri, S.; Valli, G.; Sirago, G.; Candia, J.; Hartnell, L.M.; Paganini, M.; et al. Effects of short-term unloading and active recovery on human motor unit properties, neuromuscular junction transmission and transcriptomic profile. J. Physiol. 2022, 600, 4731–4751. [Google Scholar] [CrossRef] [Scilit]
  45. Duregotti, E.; Negro, S.; Scorzeto, M.; Zornetta, I.; Dickinson, B.C.; Chang, C.J.; Montecucco, C.; Rigoni, M. Mitochondrial alarmins released by degenerating motor axon terminals activate perisynaptic Schwann cells. Proc. Natl. Acad. Sci. USA 2015, 112, E497–E505. [Google Scholar] [CrossRef] [Scilit]
  46. Heredia, D.J.; Feng, C.Y.; Hennig, G.W.; Renden, R.B.; Gould, T.W. Activity-induced Ca(2+) signaling in perisynaptic Schwann cells of the early postnatal mouse is mediated by P2Y(1) receptors and regulates muscle fatigue. Elife 2018, 7, e30839. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  47. Negro, S.; Bergamin, E.; Rodella, U.; Duregotti, E.; Scorzeto, M.; Jalink, K.; Montecucco, C.; Rigoni, M. ATP Released by Injured Neurons Activates Schwann Cells. Front. Cell Neurosci. 2016, 10, 134. [Google Scholar] [CrossRef] [Scilit]
  48. Bruneteau, G.; Bauche, S.; Gonzalez de Aguilar, J.L.; Brochier, G.; Mandjee, N.; Tanguy, M.L.; Hussain, G.; Behin, A.; Khiami, F.; Sariali, E.; et al. Endplate denervation correlates with Nogo-A muscle expression in amyotrophic lateral sclerosis patients. Ann. Clin. Transl. Neurol. 2015, 2, 362–372. [Google Scholar] [CrossRef] [Scilit]
  49. Nicole, S.; Chaouch, A.; Torbergsen, T.; Bauche, S.; de Bruyckere, E.; Fontenille, M.J.; Horn, M.A.; van Ghelue, M.; Loseth, S.; Issop, Y.; et al. Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy. Brain 2014, 137, 2429–2443. [Google Scholar] [CrossRef] [Scilit]
  50. Hastings, R.L.; Massopust, R.T.; Haddix, S.G.; Lee, Y.I.; Thompson, W.J. Exclusive vital labeling of myonuclei for studying myonuclear arrangement in mouse skeletal muscle tissue. Skelet. Muscle 2020, 10, 15. [Google Scholar] [CrossRef] [Scilit]
  51. Ham, A.S.; Lin, S.; Tse, A.; Thurkauf, M.; McGowan, T.J.; Jorin, L.; Oliveri, F.; Ruegg, M.A. Single-nuclei sequencing of skeletal muscle reveals subsynaptic-specific transcripts involved in neuromuscular junction maintenance. Nat. Commun. 2025, 16, 2220. [Google Scholar] [CrossRef] [Scilit]
  52. Motanova, E.; Sarto, F.; Negro, S.; Pirazzini, M.; Rossetto, O.; Rigoni, M.; Stashuk, D.W.; Gasparini, M.; Simunic, B.; Pisot, R.; et al. Neuromuscular junction instability with inactivity: Morphological and functional changes after 10 days of bed rest in older adults. J. Physiol. 2025, 604, 868–885. [Google Scholar] [CrossRef] [Scilit]
  53. Ying, Z.; Pan, C.; Shao, T.; Liu, L.; Li, L.; Guo, D.; Zhang, S.; Yuan, T.; Cao, R.; Jiang, Z.; et al. Mixed Lineage Kinase Domain-like Protein MLKL Breaks Down Myelin following Nerve Injury. Mol. Cell 2018, 72, 457–468.e455. [Google Scholar] [CrossRef] [Scilit]
  54. Fabbrizio, P.; Apolloni, S.; Bianchi, A.; Salvatori, I.; Valle, C.; Lanzuolo, C.; Bendotti, C.; Nardo, G.; Volonte, C. P2 × 7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis. Brain Pathol. 2020, 30, 272–282. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  55. Chen, X.; Hao, D.; Becker, N.; Muller, A.; Pishnamaz, M.; Bollheimer, L.C.; Hildebrand, F.; Nourbakhsh, M. Unsaturated Long-Chain Fatty Acids Activate Resident Macrophages and Stem Cells in a Human Skeletal Muscle Tissue Model. Biology 2023, 12, 1111. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  56. Chen, X.; Muller, A.; Pishnamaz, M.; Hildebrand, F.; Bollheimer, L.C.; Nourbakhsh, M. Differential Fatty Acid Response of Resident Macrophages in Human Skeletal Muscle Fiber and Intermuscular Adipose Tissue. Int. J. Mol. Sci. 2024, 25, 722. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  57. Chen, X.; Schubert, S.L.; Muller, A.; Pishnamaz, M.; Hildebrand, F.; Nourbakhsh, M. Metabolic Activity in Human Intermuscular Adipose Tissue Directs the Response of Resident PPARgamma(+) Macrophages to Fatty Acids. Biomedicines 2024, 13, 10. [Google Scholar] [CrossRef] [Scilit]
  58. Finlayson, S.; Palace, J.; Belaya, K.; Walls, T.J.; Norwood, F.; Burke, G.; Holton, J.L.; Pascual-Pascual, S.I.; Cossins, J.; Beeson, D. Clinical features of congenital myasthenic syndrome due to mutations in DPAGT1. J. Neurol. Neurosurg. Psychiatry 2013, 84, 1119–1125. [Google Scholar] [CrossRef] [Scilit]
  59. Monti, E.; Tagliaferri, S.; Zampieri, S.; Sarto, F.; Sirago, G.; Franchi, M.V.; Ticinesi, A.; Longobucco, Y.; Adorni, E.; Lauretani, F.; et al. Effects of a 2-year exercise training on neuromuscular system health in older individuals with low muscle function. J. Cachexia Sarcopenia Muscle 2023, 14, 794–804. [Google Scholar] [CrossRef] [Scilit]
  60. Piasecki, J.; Inns, T.B.; Bass, J.J.; Scott, R.; Stashuk, D.W.; Phillips, B.E.; Atherton, P.J.; Piasecki, M. Influence of sex on the age-related adaptations of neuromuscular function and motor unit properties in elite masters athletes. J. Physiol. 2021, 599, 193–205. [Google Scholar] [CrossRef] [Scilit]
  61. Sarto, F.; Franchi, M.V.; McPhee, J.S.; Stashuk, D.W.; Paganini, M.; Monti, E.; Rossi, M.; Sirago, G.; Zampieri, S.; Motanova, E.S.; et al. Neuromuscular impairment at different stages of human sarcopenia. J. Cachexia Sarcopenia Muscle 2024, 15, 1797–1810. [Google Scholar] [CrossRef] [Scilit]
  62. Xie, T.; Xu, G.; Liu, Y.; Quade, B.; Lin, W.; Bai, X.C. Structural insights into the assembly of the agrin/LRP4/MuSK signaling complex. Proc. Natl. Acad. Sci. USA 2023, 120, e2300453120. [Google Scholar] [CrossRef] [Scilit]
  63. Alhindi, A.; Boehm, I.; Forsythe, R.O.; Miller, J.; Skipworth, R.J.E.; Simpson, H.; Jones, R.A.; Gillingwater, T.H. Terminal Schwann cells at the human neuromuscular junction. Brain Commun. 2021, 3, fcab081. [Google Scholar] [CrossRef] [Scilit]
  64. Bakooshli, M.A.; Wang, Y.X.; Monti, E.; Su, S.; Kraft, P.; Nalbandian, M.; Alexandrova, L.; Wheeler, J.R.; Vogel, H.; Blau, H.M. Regeneration of neuromuscular synapses after acute and chronic denervation by inhibiting the gerozyme 15-prostaglandin dehydrogenase. Sci. Transl. Med. 2023, 15, eadg1485. [Google Scholar] [CrossRef] [Scilit]
  65. Ng, S.Y.; Mikhail, A.I.; Mattina, S.R.; Mohammed, S.A.; Khan, S.K.; Desjardins, E.M.; Lim, C.; Phillips, S.M.; Steinberg, G.R.; Ljubicic, V. AMPK regulates the maintenance and remodelling of the neuromuscular junction. Mol. Metab. 2025, 91, 102066. [Google Scholar] [CrossRef] [Scilit]
  66. Sakuma, M.; Gorski, G.; Sheu, S.H.; Lee, S.; Barrett, L.B.; Singh, B.; Omura, T.; Latremoliere, A.; Woolf, C.J. Lack of motor recovery after prolonged denervation of the neuromuscular junction is not due to regenerative failure. Eur. J. Neurosci. 2016, 43, 451–462. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  67. Sugimoto, T.; Sakamaki, C.; Kimura, T.; Eguchi, T.; Miura, S.; Kamei, Y. Peroxisome proliferator-activated receptor gamma coactivator 1alpha regulates downstream of tyrosine kinase-7 (Dok-7) expression important for neuromuscular junction formation. Sci. Rep. 2024, 14, 1780. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  68. Deschenes, M.R.; Rackley, M.; Fernandez, S.; Heidebrecht, M.; Hamilton, K.; Paez, H.G.; Paez, C.R.; Alway, S.E. Efficacy of Mitochondrial Transfer in Healing Toxin-Induced Damage to Neuromuscular Junction, an Empirical Study. Synapse 2025, 79, e70022. [Google Scholar] [CrossRef] [Scilit]
  69. Zhao, Y.; Yan, H.; Liu, K.; Ma, J.; Sun, W.; Lai, H.; Li, H.; Gu, J.; Huang, H. Acetylcholine receptor-beta inhibition by interleukin-6 in skeletal muscles contributes to modulating neuromuscular junction during aging. Mol. Med. 2024, 30, 171. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  70. Jones, R.A.; Reich, C.D.; Dissanayake, K.N.; Kristmundsdottir, F.; Findlater, G.S.; Ribchester, R.R.; Simmen, M.W.; Gillingwater, T.H. NMJ-morph reveals principal components of synaptic morphology influencing structure-function relationships at the neuromuscular junction. Open Biol. 2016, 6, 160240, Correction in Open Biol. 2017, 7, 160335. [Google Scholar] [CrossRef] [Scilit]
  71. Sun, S.; Shen, Y.; Zhang, X.; Ding, N.; Xu, Z.; Zhang, Q.; Li, L. The MuSK agonist antibody protects the neuromuscular junction and extends the lifespan in C9orf72-ALS mice. Mol. Ther. 2024, 32, 2176–2189. [Google Scholar] [CrossRef] [Scilit]
  72. Haddix, S.G.; Lee, Y.I.; Kornegay, J.N.; Thompson, W.J. Cycles of myofiber degeneration and regeneration lead to remodeling of the neuromuscular junction in two mammalian models of Duchenne muscular dystrophy. PLoS ONE 2018, 13, e0205926. [Google Scholar] [CrossRef] [Scilit]
  73. Tsuchiya, M.; Hara, Y.; Okuda, M.; Itoh, K.; Nishioka, R.; Shiomi, A.; Nagao, K.; Mori, M.; Mori, Y.; Ikenouchi, J.; et al. Cell surface flip-flop of phosphatidylserine is critical for PIEZO1-mediated myotube formation. Nat. Commun. 2018, 9, 2049. [Google Scholar] [CrossRef] [Scilit]
  74. Bermedo-García, F.; Zelada, D.; Martínez, E.; Tabares, L.; Henríquez, J.P. Functional regeneration of the murine neuromuscular synapse relies on long-lasting morphological adaptations. Bmc Biol. 2022, 20, 158. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  75. Hastings, R.L.; Mikesh, M.; Lee, Y.I.; Thompson, W.J. Morphological remodeling during recovery of the neuromuscular junction from terminal Schwann cell ablation in adult mice. Sci. Rep. 2020, 10, 11132. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  76. Lu, J.C.Y.; Huang, Y.H.; Chen, A.C.Y.; Chuang, D.C.C. Using the Neuromuscular Junction Cellular Response to Predict Functional Recovery after Nerve Grafting in a Mouse Experimental Model. Plast. Reconstr. Surg. 2024, 154, 551–561. [Google Scholar] [CrossRef] [Scilit]
  77. Gupta, R.; Johnston, T.R.; Chen, V.Y.; Gonzales, L.P.; Steward, O. Human Motor Endplate Survival after Chronic Peripheral Nerve Injury. medRxiv 2023. [Google Scholar] [CrossRef] [Scilit]
  78. Wokke, J.H.J.; Jennekens, F.G.I.; Vandenoord, C.J.M.; Veldman, H.; Smit, L.M.E.; Leppink, G.J. Morphological-Changes in the Human End Plate with Age. J. Neurol. Sci. 1990, 95, 291–310. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  79. Lexell, J.; Taylor, C.C.; Sjostrom, M. What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J. Neurol. Sci. 1988, 84, 275–294. [Google Scholar] [CrossRef] [Scilit]
  80. Chang, M.Y.; Liu, R.Q.; Chen, B.Q.; Xu, J.; Wang, W.; Ji, Y.N.; Gao, Z.H.; Liu, B.Y.; Yao, X.L.; Sun, H.L.; et al. hBMSC-EVs alleviate weightlessness-induced skeletal muscle atrophy by suppressing oxidative stress and inflammation. Stem Cell Res. Ther. 2025, 16, 46. [Google Scholar] [CrossRef] [Scilit]
  81. Southerland, K.W.; Xu, Y.; Peters, D.T.; Wei, X.; Lin, X.; Xiang, Y.; Fei, K.; Olivere, L.A.; Morowitz, J.M.; Otto, J.; et al. Pro-inflammatory macrophages impair skeletal muscle regeneration in ischemic-damaged limbs by inducing precocious differentiation of satellite cells. bioRxiv 2023. [Google Scholar] [CrossRef] [Scilit]
  82. Wang, S.; Wang, S.; Cai, W.; Wang, J.; Huang, J.; Yang, Q.; Bai, H.; Jiang, B.; Ben, J.; Zhang, H.; et al. Macrophage scavenger receptor A1 promotes skeletal muscle regeneration after hindlimb ischemia. J. Biomed. Res. 2024, 39, 23–35. [Google Scholar] [CrossRef] [Scilit]
  83. Qin, H.; Luo, Z.; Sun, Y.; He, Z.; Qi, B.; Chen, Y.; Wang, J.; Li, C.; Lin, W.; Han, Z.; et al. Low-intensity pulsed ultrasound promotes skeletal muscle regeneration via modulating the inflammatory immune microenvironment. Int. J. Biol. Sci. 2023, 19, 1123–1145. [Google Scholar] [CrossRef] [Scilit]
  84. Mane-Damas, M.; Schottler, A.K.; Marcuse, F.; Molenaar, P.C.; Mohile, T.; Hoeijmakers, J.G.J.; Hochstenbag, M.; Damoiseaux, J.; Maessen, J.G.; Abdul-Hamid, M.; et al. Myasthenia gravis with antibodies against the AChR, current knowledge on pathophysiology and an update on treatment strategies with special focus on targeting plasma cells. Autoimmun. Rev. 2025, 24, 103875. [Google Scholar] [CrossRef] [Scilit]
  85. Wang, B.; Liu, D.; Yang, Y.; Zhu, R. Beyond the Surface: Investigating the Potential Mechanisms of Non-Motor Symptoms in Myasthenia Gravis. Eur. J. Neurol. 2025, 32, e70309. [Google Scholar] [CrossRef] [Scilit]
  86. Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.P.; Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010, 39, 412–423. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  87. Lee, L.L.; Galo, E.; Lyeth, B.G.; Muizelaar, J.P.; Berman, R.F. Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker. Exp. Neurol. 2004, 190, 70–78. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  88. Rygiel, K.A.; Picard, M.; Turnbull, D.M. The ageing neuromuscular system and sarcopenia: A mitochondrial perspective. J. Physiol. 2016, 594, 4499–4512. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  89. Ohno, K.; Ohkawara, B.; Shen, X.M.; Selcen, D.; Engel, A.G. Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes—A Comprehensive Review. Int. J. Mol. Sci. 2023, 24, 3730. [Google Scholar] [CrossRef] [Scilit]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.